Base de dados : MEDLINE
Pesquisa : E01.354.506 [Categoria DeCS]
Referências encontradas : 26135 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2614 ir para página                         

  1 / 26135 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452485
[Au] Autor:Li H; Park J; Kim H; Hwang KB; Paek E
[Ad] Endereço:School of Computer Science and Engineering, Soongsil University , Seoul 06978, Republic of Korea.
[Ti] Título:Systematic Comparison of False-Discovery-Rate-Controlling Strategies for Proteogenomic Search Using Spike-in Experiments.
[So] Source:J Proteome Res;16(6):2231-2239, 2017 Jun 02.
[Is] ISSN:1535-3907
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Proteogenomic searches are useful for novel peptide identification from tandem mass spectra. Usually, separate and multistage approaches are adopted to accurately control the false discovery rate (FDR) for proteogenomic search. Their performance on novel peptide identification has not been thoroughly evaluated, however, mainly due to the difficulty in confirming the existence of identified novel peptides. We simulated a proteogenomic search using a controlled, spike-in proteomic data set. After confirming that the results of the simulated proteogenomic search were similar to those of a real proteogenomic search using a human cell line data set, we evaluated the performance of six FDR control methods-global, separate, and multistage FDR estimation, respectively, coupled to a target-decoy search and a mixture model-based method-on novel peptide identification. The multistage approach showed the highest accuracy for FDR estimation. However, global and separate FDR estimation with the mixture model-based method showed higher sensitivities than others at the same true FDR. Furthermore, the mixture model-based method performed equally well when applied without or with a reduced set of decoy sequences. Considering different prior probabilities for novel and known protein identification, we recommend using mixture model-based methods with separate FDR estimation for sensitive and reliable identification of novel peptides from proteogenomic searches.
[Mh] Termos MeSH primário: Peptídeos/análise
Proteogenômica/métodos
[Mh] Termos MeSH secundário: Linhagem Celular
Simulação por Computador
Reações Falso-Positivas
Seres Humanos
Métodos
Modelos Teóricos
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Peptides)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jproteome.7b00033


  2 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465605
[Au] Autor:Wang R; Zhou K; Fan Q; Chen H; Fan C
[Ad] Endereço:Department of Nuclear Medicine, West China Hospital of Sichuan University, Guoxue Alley, Chengdu, Sichuan, People's Republic of China.
[Ti] Título:A false-positive I-131 finding of duodenum diverticulum in thyroid cancer evaluation by SPECT/CT: A case report.
[So] Source:Medicine (Baltimore);97(8):e9997, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Iodine-131 (I-131) is a sensitive marker for the detection of differentiated thyroid cancer (DTC). I-131 whole-body scintigraphy (WBS) has been used widely in evaluation of DTC patient. However, I-131 WBS exists many false-positive uptake of I-131 because radioiodine uptake can also be seen in healthy tissue or in a variety of benign and malignant non-thyroidal tumors. PATIENT CONCERNS: A 44-year-old woman with a papillary thyroid carcinoma for the purpose of ablation therapy after a total thyroidectomy. I-131 WBS showed intensive uptake by thyroid remnant. Meanwhile, a focus of increased activity was seen in right upper abdomen. DISGNOSES, INTERVENTIONS AND OUTCOMES: Based on an I-131 single-photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging combining a Tc-99m pertechnetate dynamic SPECT scan and SPECT/CT fusion imaging with oral administration of iodine contrast agent, a descending duodenum diverticulum was diagnosed. This patient was then treated with conservative treatment, such as diet regulation, rest, appropriate use of antacids and antispasmodic agents, etc. So far, she recovered uneventfully with no any complications. LESSONS: Duodenum diverticulum is a rare false-positive uptake of I-131, it might be a diagnostic challenge when there are many false-positive uptake of I-131 in evaluation of DTC. So it must be significant to be familiar with these physiologic and pathologic variants of I-131 uptake and make further efforts to accurately interpret radioiodine scintigraphy results.
[Mh] Termos MeSH primário: Divertículo/diagnóstico por imagem
Duodenopatias/diagnóstico por imagem
Radioisótopos do Iodo
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único
Neoplasias da Glândula Tireoide/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Carcinoma Papilar
Divertículo/etiologia
Duodenopatias/etiologia
Reações Falso-Positivas
Feminino
Seres Humanos
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodine Radioisotopes); 0 (Iodine-131)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009997


  3 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29450531
[Au] Autor:Grossman DC; Curry SJ; Owens DK; Barry MJ; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Krist AH; Kurth AE; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; US Preventive Services Task Force
[Ad] Endereço:Kaiser Permanente Washington Health Research Institute, Seattle.
[Ti] Título:Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.
[So] Source:JAMA;319(6):588-594, 2018 02 13.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: With approximately 14 000 deaths per year, ovarian cancer is the fifth most common cause of cancer death among US women and the leading cause of death from gynecologic cancer. More than 95% of ovarian cancer deaths occur among women 45 years and older. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on screening for ovarian cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for ovarian cancer in asymptomatic women not known to be at high risk for ovarian cancer (ie, high risk includes women with certain hereditary cancer syndromes that increase their risk for ovarian cancer). Outcomes of interest included ovarian cancer mortality, quality of life, false-positive rate, surgery and surgical complication rates, and psychological effects of screening. Findings: The USPSTF found adequate evidence that screening for ovarian cancer does not reduce ovarian cancer mortality. The USPSTF found adequate evidence that the harms from screening for ovarian cancer are at least moderate and may be substantial in some cases, and include unnecessary surgery for women who do not have cancer. Given the lack of mortality benefit of screening, and the moderate to substantial harms that could result from false-positive screening test results and subsequent surgery, the USPSTF concludes with moderate certainty that the harms of screening for ovarian cancer outweigh the benefit, and the net balance of the benefit and harms of screening is negative. Conclusions and Recommendation: The USPSTF recommends against screening for ovarian cancer in asymptomatic women. (D recommendation) This recommendation applies to asymptomatic women who are not known to have a high-risk hereditary cancer syndrome.
[Mh] Termos MeSH primário: Detecção Precoce de Câncer
Programas de Rastreamento
Neoplasias Ovarianas/diagnóstico
[Mh] Termos MeSH secundário: Doenças Assintomáticas
Detecção Precoce de Câncer/efeitos adversos
Reações Falso-Positivas
Feminino
Seres Humanos
Programas de Rastreamento/efeitos adversos
Neoplasias Ovarianas/mortalidade
Qualidade de Vida
Medição de Risco
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180217
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.21926


  4 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29450530
[Au] Autor:Henderson JT; Webber EM; Sawaya GF
[Ad] Endereço:Kaiser Permanente Research Affiliates Evidence-based Practice Center, Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.
[Ti] Título:Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
[So] Source:JAMA;319(6):595-606, 2018 02 13.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Ovarian cancer is relatively rare but the fifth-leading cause of cancer mortality among United States women. Objective: To systematically review evidence on benefits and harms of ovarian cancer screening among average-risk women to inform the United States Preventive Services Task Force. Data Sources: MEDLINE, PubMed, Cochrane Collaboration Registry of Controlled Trials; studies published in English from January 1, 2003, through January 31, 2017; ongoing surveillance in targeted publications through November 22, 2017. Study Selection: Randomized clinical trials of ovarian cancer screening in average-risk women that reported mortality or quality-of-life outcomes. Interventions included transvaginal ultrasound, cancer antigen 125 (CA-125) testing, or their combination. Comparators were usual care or no screening. Data Extraction and Synthesis: Independent critical appraisal and data abstraction by 2 reviewers. Meta-analytic pooling of results was not conducted because of the small number of studies and heterogeneity of interventions. Main Outcomes and Measures: Ovarian cancer mortality, false-positive screening results and surgery, surgical complications, and psychological effects of screening. Results: Four trials (N = 293 587) were included; of these, 3 (n = 293 038) assessed ovarian cancer mortality, and 1 (n = 549) reported only on psychological outcomes. Evaluated screening interventions included transvaginal ultrasound alone, transvaginal ultrasound plus CA-125 testing, and CA-125 testing alone. Test positivity for CA-125 was defined by a fixed serum level cutpoint or by a proprietary risk algorithm based on CA-125 level, change in CA-125 level over time, and age (risk of ovarian cancer algorithm [ROCA]). No trial found a significant difference in ovarian cancer mortality with screening. In the 2 large screening trials (PLCO and UKCTOCS, n = 271 103), there was not a statistically significant difference in complete intention-to-screen analyses of ovarian, fallopian, and peritoneal cancer cases associated with screening (PLCO: rate ratio, 1.18 [95% CI, 0.82-1.71]; UKCTOCS: hazard ratio [HR], 0.91 [95% CI, 0.76-1.09] for transvaginal ultrasound and HR, 0.89 [95% CI, 0.74-1.08] for CA-125 ROCA). Within these 2 trials, screening led to surgery for suspected ovarian cancer in 1% of women without cancer for CA-125 ROCA and in 3% for transvaginal ultrasound with or without CA-125 screening, with major complications occurring among 3% to 15% of surgery. Evidence on psychological harms was limited but nonsignificant except in the case of repeat follow-up scans and tests, which increased the risk of psychological morbidity in a subsample of UKCTOCS participants based on the General Health Questionnaire 12 (score ≥4) (odds ratio, 1.28 [95% CI, 1.18-1.39]). Conclusions and Relevance: In randomized trials conducted among average-risk, asymptomatic women, ovarian cancer mortality did not significantly differ between screened women and those with no screening or in usual care. Screening harms included surgery (with major surgical complications) in women found to not have cancer. Further research is needed to identify effective approaches for reducing ovarian cancer incidence and mortality.
[Mh] Termos MeSH primário: Detecção Precoce de Câncer
Programas de Rastreamento
Neoplasias Ovarianas/diagnóstico
[Mh] Termos MeSH secundário: Doenças Assintomáticas
Antígeno Ca-125/sangue
Detecção Precoce de Câncer/métodos
Reações Falso-Positivas
Feminino
Seres Humanos
Programas de Rastreamento/efeitos adversos
Neoplasias Ovarianas/mortalidade
Ensaios Clínicos Controlados Aleatórios como Assunto
Medição de Risco
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; REVIEW
[Nm] Nome de substância:
0 (CA-125 Antigen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180217
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.21421


  5 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29420464
[Au] Autor:Vora NM; Orciari LA; Bertumen JB; Damon I; Ellison JA; Fowler VG; Franka R; Petersen BW; Satheshkumar PS; Schexnayder SM; Smith TG; Wallace RM; Weinstein S; Williams C; Yager P; Niezgoda M
[Ti] Título:Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin.
[So] Source:MMWR Morb Mortal Wkly Rep;67(5):161-165, 2018 Feb 09.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Rabies is an acute encephalitis that is nearly always fatal. It is caused by infection with viruses of the genus Lyssavirus, the most common of which is Rabies lyssavirus. The Council of State and Territorial Epidemiologists (CSTE) defines a confirmed human rabies case as an illness compatible with rabies that meets at least one of five different laboratory criteria.* Four of these criteria do not depend on the patient's rabies vaccination status; however, the remaining criterion, "identification of Lyssavirus-specific antibody (i.e. by indirect fluorescent antibody…test or complete [Rabies lyssavirus] neutralization at 1:5 dilution) in the serum," is only considered diagnostic in unvaccinated patients. Lyssavirus-specific antibodies include Rabies lyssavirus-specific binding immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies and Rabies lyssavirus neutralizing antibodies (RLNAs). This report describes six patients who were tested for rabies by CDC and who met CSTE criteria for confirmed human rabies because they had illnesses compatible with rabies, had not been vaccinated for rabies, and were found to have serum RLNAs (with complete Rabies lyssavirus neutralization at a serum dilution of 1:5). An additional four patients are described who were tested for rabies by CDC who were found to have serum RLNAs (with incomplete Rabies lyssavirus neutralization at a serum dilution of 1:5) despite having not been vaccinated for rabies. None of these 10 patients received a rabies diagnosis; rather, they were considered to have been passively immunized against rabies through recent receipt of intravenous immune globulin (IVIG). Serum RLNA test results should be interpreted with caution in patients who have not been vaccinated against rabies but who have recently received IVIG.
[Mh] Termos MeSH primário: Imunoglobulinas Intravenosas/administração & dosagem
Raiva/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Reações Falso-Positivas
Feminino
Seres Humanos
Imunização Passiva
Lyssavirus/isolamento & purificação
Masculino
Meia-Idade
Vacinas Antirrábicas/administração & dosagem
Vírus da Raiva/isolamento & purificação
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulins, Intravenous); 0 (Rabies Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6705a3


  6 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29323852
[Au] Autor:Gurtsevitch VE; Senyuta NB; Lomaya MV; Ignatova AV; Dushenkina TE; Repkina IA; Pavlovskaya AI; Mudunov AM
[Ti] Título:Diagnostic value of the Epstein-Barr virus serological markers in patients with nasopharyngeal carcinoma in cases of undetectable primary tumor location.
[So] Source:Vopr Virusol;61(5):205-12, 2016.
[Is] ISSN:0507-4088
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The goal of this work was to describe a method for diagnosis of the non-keratinizing nasopharyngeal carcinoma (nNPC) in cases of the undetectable primary tumor location. The method is based on evaluation of IgG and IgA antibody levels to the capsid (VCA) and early antigens (EA) of the Epstein-Barr virus (EBV). The diagnosis of nNPC is established by a so-called decision rule. The latter was created by mathematical processing of the method of multifactor analysis of the results of anti-EBV antibody testing of 72 patients with clinically and morphologically confirmed nNPC and 72 patients with other head and neck benign tumors (OHNT) not associated with EBV, which were tested as a control group. The diagnostic value of the decision rule which was tested in the group of 77 patients with confirmed nNPC and 231 patients of a control group was high. The numbers of false negative and false positive cases were equal to 5.2% (4/77) and 6.5% (17/231), respectively. Among 32 patients with undetectable primary tumors the decision rule was able to identify 11 cases of nNPC. This diagnosis later was confirmed by morphological and instrumental methods of study. Only in two cases, false negative result was obtained (2/32; 6.3%) indicating that the serological diagnostics of nNPC with the decision rule is highly specific but not exact. Thus, the data obtained allowed us to conclude that the serological testing of EBV specific antibody evaluated by the decision rule can be recommended as an important test supplementing the standard methods of pdNPC diagnostics including cases with undetected primary tumor location.
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Carcinoma/diagnóstico
Tomada de Decisão Clínica/métodos
Infecções por Vírus Epstein-Barr/diagnóstico
Neoplasias de Cabeça e Pescoço/diagnóstico
Neoplasias Nasofaríngeas/diagnóstico
Neoplasias/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos Virais/sangue
Antígenos Virais/imunologia
Biomarcadores/sangue
Proteínas do Capsídeo/sangue
Proteínas do Capsídeo/imunologia
Carcinoma/complicações
Carcinoma/imunologia
Carcinoma/virologia
Estudos de Casos e Controles
Infecções por Vírus Epstein-Barr/complicações
Infecções por Vírus Epstein-Barr/imunologia
Infecções por Vírus Epstein-Barr/virologia
Análise Fatorial
Reações Falso-Negativas
Reações Falso-Positivas
Feminino
Neoplasias de Cabeça e Pescoço/complicações
Neoplasias de Cabeça e Pescoço/imunologia
Neoplasias de Cabeça e Pescoço/virologia
Herpesvirus Humano 4/imunologia
Herpesvirus Humano 4/isolamento & purificação
Seres Humanos
Imunoglobulina A/sangue
Imunoglobulina G/sangue
Masculino
Neoplasias Nasofaríngeas/complicações
Neoplasias Nasofaríngeas/imunologia
Neoplasias Nasofaríngeas/virologia
Neoplasias/complicações
Neoplasias/imunologia
Neoplasias/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Biomarkers); 0 (Capsid Proteins); 0 (Immunoglobulin A); 0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE


  7 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320551
[Au] Autor:Navarro-Lozano A; Sánchez-Domene D; Rossa-Feres DC; Bosch J; Sawaya RJ
[Ad] Endereço:Departamento de Zoologia e Botânica. Universidade Estadual Paulista, São José do Rio Preto, São Paulo, Brazil.
[Ti] Título:Are oral deformities in tadpoles accurate indicators of anuran chytridiomycosis?
[So] Source:PLoS One;13(1):e0190955, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We evaluated the use of oral deformities as reliable proxies for determining Batrachochytrium dendrobatidis (Bd) infection in tadpoles of six anuran species of the Atlantic Forest in southeastern Brazil. We examined oral discs of 2156 tadpoles of six species of anurans collected in 2016: Aplastodiscus albosignatus, Boana albopunctata, Boana faber, Scinax hayii, Crossodactylus caramaschii, and Physalaemus cuvieri. Three oral deformities were recognized: lack of keratinization only in upper and/or lower jaw sheaths, lack of keratinization only in upper or lower tooth rows, and both deformities together. A subsample composed of all the individuals possessing oral deformities (N = 195) plus randomly selected individuals without oral deformities (N = 184) were tested for Bd via qPCR. Oral deformities were observed in all six species, but only five were infected with Bd. Since we found that dekeratinization of tooth rows was not associated with the presence of Bd in any of the studied species we used a new proxy (jaw sheaths dekeratinization with or without dekeratinization in tooth rows: JSD-proxy) for Bd detection. Our results showed a nonrandom relationship between Bd infection and JSD-proxy in three species of the family Hylidae. However, the use of JSD-proxy for Bd detection in these species resulted in up to 30.8% false positives and up to 29.3% false negatives. The use of the JSD-proxy in species for which no relationship was found reached 100% of false positives. We conclude that the use of oral dekeratinization as a generalized proxy for Bd detection in tadpoles should not be used as a single diagnosis technique.
[Mh] Termos MeSH primário: Anuros/microbiologia
Quitridiomicetos
Larva/microbiologia
Boca/patologia
Micoses/veterinária
[Mh] Termos MeSH secundário: Animais
Reações Falso-Negativas
Reações Falso-Positivas
Queratinas
Micoses/diagnóstico
Micoses/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
68238-35-7 (Keratins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190955


  8 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29038002
[Au] Autor:Guichet E; Serrano L; Laurent C; Eymard-Duvernay S; Kuaban C; Vidal L; Delaporte E; Ngole EM; Ayouba A; Peeters M
[Ad] Endereço:UMI233-TransVIHMI/INSERM U1175, Institut de Recherche pour le Développement (IRD) and University of Montpellier, Montpellier, France.
[Ti] Título:Comparison of different nucleic acid preparation methods to improve specific HIV-1 RNA isolation for viral load testing on dried blood spots.
[So] Source:J Virol Methods;251:75-79, 2018 Jan.
[Is] ISSN:1879-0984
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In resource-limited countries (RLCs), WHO recommends HIV viral load (VL) on dried blood spots (DBS) for antiretroviral therapy (ART) monitoring of patients living in non-urban settings where plasma VL is not available. In order to reduce the impact of proviral DNA interference, leading to false positive results in samples with low plasma VL, we compared three different nucleic acid preparation methods with the NucliSens (Biomérieux) extraction, known for its high recovery of nucleic acids on DBS. Paired plasma-DBS samples (n=151) with predominantly low plasma VL (≤10,000 copies/ml; 74%) were used. At the threshold of 1,000 copies/ml on DBS, 51% and 10% were misclassified as false positives or false negatives, respectively with NucliSens, versus 41% and 20% with m2000sp (Abbott), described as more specific for RNA recovery. DNase treatments of nucleic acid extracts and free virus elution (FVE) protocol before nucleic acid extraction, reduced the proportion of false positives to 0% and 19%, but increased the proportion of false negatives to 40% and 73%. More efforts are thus still needed to improve performance of VL assays on DBS to monitor patients on ART in RLCs and allow timely switch to more costly second or third line ART regimes.
[Mh] Termos MeSH primário: Infecções por HIV/virologia
HIV-1/isolamento & purificação
Plasma/virologia
RNA Viral/análise
RNA Viral/isolamento & purificação
Manejo de Espécimes/métodos
Carga Viral/métodos
[Mh] Termos MeSH secundário: Reações Falso-Negativas
Reações Falso-Positivas
Seres Humanos
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Viral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171018
[St] Status:MEDLINE


  9 / 26135 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746261
[Au] Autor:McAuliffe GN; Taylor SL; Drinkovic D; Roberts SA; Wilson EM; Best EJ
[Ad] Endereço:From the *Microbiology Department, Auckland City Hospital, †Microbiology Department, Middlemore Hospital, ‡Microbiology Department, North Shore Hospital, and §Department of Paediatric Infectious Diseases, Starship Children's Hospital, Auckland, New Zealand.
[Ti] Título:Rotavirus Infection in the Auckland Region After the Implementation of Universal Infant Rotavirus Vaccination: Impact on Hospitalizations and Laboratory Implications.
[So] Source:Pediatr Infect Dis J;37(1):e1-e5, 2018 Jan.
[Is] ISSN:1532-0987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In July 2014, New Zealand introduced universal infant vaccination with RotaTeq (Merk & Co.) administered as 3 doses at 6 weeks, 3 and 5 months of age. We sought to assess the impact of rotavirus vaccination on gastroenteritis (GE) hospitalizations in the greater Auckland region and analyze changes in rotavirus testing in the period around vaccine introduction. METHODS: Hospitalizations, laboratory testing rates and methods were compared between the pre-vaccine period (2009-2013), post-vaccine period (January 2015 to December 2015) and year of vaccine introduction (2014). RESULTS: There was a 68% decline in rotavirus hospitalizations of children <5 years of age after vaccine introduction (from 258/100,000 to 83/100,000) and a 17% decline in all-cause gastroenteritis admissions (from 1815/100,000 to 1293/100,000). Reductions were also seen in pediatric groups too old to have received vaccine. Despite these changes, rotavirus testing rates in our region remained static in the year after vaccine introduction compared with the 2 prior years, and after vaccine introduction, we observed a high rate of false positives 19/58 (33%) in patients with reactive rotavirus tests. CONCLUSIONS: Rotavirus vaccine has had a significant early impact on gastroenteritis hospitalizations for children in the Auckland region. However, continued rotavirus testing at pre-vaccine rates risks generating false positive results. Laboratories and clinicians should consider reviewing their testing algorithms before vaccine introduction.
[Mh] Termos MeSH primário: Gastroenterite/epidemiologia
Hospitalização/estatística & dados numéricos
Técnicas Microbiológicas/estatística & dados numéricos
Infecções por Rotavirus/epidemiologia
Vacinas contra Rotavirus
Vacinação/estatística & dados numéricos
[Mh] Termos MeSH secundário: Pré-Escolar
Reações Falso-Positivas
Gastroenterite/prevenção & controle
Gastroenterite/virologia
Seres Humanos
Lactente
Recém-Nascido
Técnicas Microbiológicas/utilização
Nova Zelândia/epidemiologia
Rotavirus
Infecções por Rotavirus/prevenção & controle
Infecções por Rotavirus/virologia
Vacinas Atenuadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RotaTeq); 0 (Rotavirus Vaccines); 0 (Vaccines, Attenuated)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180110
[Lr] Data última revisão:
180110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1097/INF.0000000000001706


  10 / 26135 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29213153
[Au] Autor:Céspedes N; Valencia A; Echeverry CA; Arce-Plata MI; Colón C; Castiñeiras DE; Hurtado PM; Cocho JA; Herrera S; Arévalo-Herrera M
[Ad] Endereço:Malaria Vaccine and Drug Development Center (MVDC), Cali, Colombia.
[Ti] Título:Reference values of amino acids, acylcarnitines and succinylacetone by tandem mass spectrometry for use in newborn screening in southwest Colombia.
[So] Source:Colomb Med (Cali);48(3):113-119, 2017 Sep 30.
[Is] ISSN:1657-9534
[Cp] País de publicação:Colombia
[La] Idioma:eng
[Ab] Resumo:Introduction: Inborn errors of metabolism (IEM) represent an important public health problem due to current diagnosis and treatment limitations, poor life quality of affected patients, and consequent untimely child death. In contrast to classical methods, tandem mass spectrometry (MS/MS) has allowed simultaneous evaluation of multiple metabolites associated with IEM offering higher sensitivity, low false positive rates and high throughput. Aims: Determine concentration levels for amino acids and acylcarnitines in blood of newborns from Colombia, to establish reference values for further use in diagnosis of IEM. Methods: Implementation of a method to determine amino acids, acylcarnitines and succinylacetone in newborn dried blood spots using MS/MS, and its application in a cross-sectional study conducted in 891 healthy neonates from Cali and Quibdo cities is described. Results: fifty-seven analytes that allow the diagnosis of more than 40 different pathologies were tested. The method showed to be linear, precise and accurate. Healthy neonates 1-18 days of age were included, 523 from Cali and 368 from Quibdo; 52% male and 48% female. Age-related differences on the concentration levels of amino acids and acylcarnitines were observed whereas no significant differences by gender were found. Conclusion: The study has contributed to reveal the usual concentration levels of amino acids, acylcarnitines and succinylacetone that could be used as reference for the establishment of a newborn metabolic screening program in Colombia.
[Mh] Termos MeSH primário: Aminoácidos/sangue
Carnitina/análogos & derivados
Heptanoatos/sangue
Erros Inatos do Metabolismo/diagnóstico
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Carnitina/sangue
Colômbia
Estudos Transversais
Reações Falso-Positivas
Seres Humanos
Recém-Nascido
Erros Inatos do Metabolismo/sangue
Valores de Referência
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Biomarkers); 0 (Heptanoates); 0 (acylcarnitine); 51568-18-4 (succinylacetone); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180109
[Lr] Data última revisão:
180109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.25100/cm.v48i3.2180



página 1 de 2614 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde